Clinical characteristics, treatment and outcome of nivolumab-induced myasthenia gravis

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM et al Management of Immune-Related adverse events in patients treated with Immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2018 Jun10;36(17):1714–1768. doi: https://doi.org/10.1200/JCO.2017.77.6385

Rajan A, Kim C, Heery CR, Guha U, Gulley JL (2016) Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: role in advanced cancers. Hum Vaccin Immunother 12(9):2219–2231. https://doi.org/10.1080/21645515.2016.1175694

Article  PubMed  PubMed Central  Google Scholar 

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26(12):2375–2391. https://doi.org/10.1093/annonc/mdv383

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS et al (2000 Jul) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg 70(1):327–334. https://doi.org/10.1016/s0003-4975(00)01595-2

Tomschik M, Hilger E, Rath J, Mayer EM, Fahrner M, Cetin H et al (2020) Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology 95(10):e1426–e1436. https://doi.org/10.1212/WNL.0000000000010209

Article  PubMed  Google Scholar 

Gilhus NE, Myasthenia Gravis (2016) N Engl J Med 375(26):2570–2581. https://doi.org/10.1056/NEJMra1602678

Article  CAS  PubMed  Google Scholar 

Kao JC, Brickshawana A, Liewluck T (2018) Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep 18(10):63. https://doi.org/10.1007/s11910-018-0878-7

Article  CAS  PubMed  Google Scholar 

Suzuki S, Ishikawa N, Konoeda F, Seki N, Fukushima S, Takahashi K et al (2017) Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89(11):1127–1134. https://doi.org/10.1212/WNL.0000000000004359

Article  CAS  PubMed  Google Scholar 

Tan RYC, Toh CK, Takano A (2017) Continued response to one dose of Nivolumab complicated by Myasthenic Crisis and Myositis. J Thorac Oncol 12(7):e90–e91. https://doi.org/10.1016/j.jtho.2017.02.024

Article  PubMed  Google Scholar 

Klein SL, Marriott I, Fish EN (2015) Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg 109(1):9–15. https://doi.org/10.1093/trstmh/tru167

Article  CAS  PubMed  PubMed Central  Google Scholar 

MMarkle JG, Fish EN (2014) SeXX matters in immunity. Trends Immunol 35(3):97–104. https://doi.org/10.1016/j.it.2013.10.006

Article  CAS  Google Scholar 

Montes V, Sousa S, Pita F, Guerreiro R, Carmona C (2018) Myasthenia Gravis Induced by Ipilimumab in a patient with metastatic melanoma. Front Neurol 9:150. https://doi.org/10.3389/fneur.2018.00150

Article  PubMed  PubMed Central  Google Scholar 

Johnson DB, Saranga-Perry V, Lavin PJ, Burnette WB, Clark SW, Uskavitch DR et al (2015) Myasthenia Gravis Induced by Ipilimumab in patients with metastatic melanoma. J Clin Oncol 33(33):e122–e124. https://doi.org/10.1200/JCO.2013.51.1683

Article  PubMed  PubMed Central  Google Scholar 

Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S (2014) Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 16(4):589–593. https://doi.org/10.1093/neuonc/nou001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Purvin V, Kawasaki A, Smith KH, Kesler A (2006) Statin-associated myasthenia gravis: report of 4 cases and review of the literature. Med (Baltim) 85(2):82–85. https://doi.org/10.1097/01.md.0000209337.59874.aa

Article  Google Scholar 

Agrawal N, Khunger A, Vachhani P, Colvin TA, Hattoum A, Spangenthal E et al (2019) Cardiac Toxicity Associated with Immune Checkpoint inhibitors: Case Series and Review of the literature. Case Rep Oncol 12(1):260–276. https://doi.org/10.1159/000498985

Article  CAS  PubMed  PubMed Central  Google Scholar 

Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME et al (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319. https://doi.org/10.1186/s40425-019-0774-y

Article  PubMed  PubMed Central  Google Scholar 

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE et al (2019) Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Cancer Netw 17:255–289. https://doi.org/10.6004/jnccn.2019.0013

Article  CAS  Google Scholar 

Tahir N, Mahboob A, Piao X, Ying G, Shrestha J, Sherchan R, Zahra F (2021) Nivolumab, a double-edged Sword: a Case Report of Nivolumab-Induced Myasthenia Gravis. J Med Cases 12(10):424–428. https://doi.org/10.14740/jmc3783

Article  PubMed  PubMed Central  Google Scholar 

Miñón-Fernández B, Losada-Domingo JM, Sánchez-Horvath MT, Bárcena-Llona J (2020) Myasthenia gravis associated with nivolumab. Rev Neurol 70(2):72–73 Spanish. https://doi.org/10.33588/rn.7002.2019153

Article  PubMed  Google Scholar 

Dhenin A, Samartzi V, Lejeune S, Seront E (2019) Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ Case Rep 12(6):e229149. https://doi.org/10.1136/bcr-2018-229149

Article  PubMed  PubMed Central  Google Scholar 

Miller RG, Milner-Brown HS, Mirka A (1986) Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology 36(5):729–732. https://doi.org/10.1212/wnl.36.5.729

Article  CAS  PubMed  Google Scholar 

Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 update. Neurology 96(3):114–122. https://doi.org/10.1212/WNL.0000000000011124

Article  PubMed  PubMed Central  Google Scholar 

Becquart O, Lacotte J, Malissart P, Nadal J, Lesage C, Guillot B, Du Thanh A (2019) Myasthenia Gravis Induced by Immune Checkpoint inhibitors. J Immunother 42(8):309–312. https://doi.org/10.1097/CJI.0000000000000278

Article  CAS  PubMed  Google Scholar 

Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A et al (2019) PD-1 inhibitors-related neurological toxicities in patients with non-small-cell Lung Cancer: A literature review. Cancers (Basel) 11(3):296. https://doi.org/10.3390/cancers11030296

Article  CAS  PubMed  Google Scholar 

Maeda O, Yokota K, Atsuta N, Katsuno M, Akiyama M, Ando Y (2016) Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci 78(1):119–122. https://doi.org/10.18999/NAGJMS.78.1.119

Article  PubMed  PubMed Central  Google Scholar 

Werner JM, Schweinsberg V, Schroeter M, von Reutern B, Malter MP, Schlaak M et al (2019) Successful treatment of Myasthenia Gravis following PD-1/CTLA-4 combination checkpoint blockade in a patient with metastatic melanoma. Front Oncol 9:84. https://doi.org/10.3389/fonc.2019.00084

Article  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif